SCHEMBL6132300

SCHEMBL6132300

COC(=O)c1ccc(-c2ccc(N3CCN(c4ccc(OC)cc4)CC3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
L3MBTL1 Q9Y468 2/20 0.61
ALDH1A1 P00352 6/20 0.60
POLB P06746 3/20 0.60
RAB9A P51151 2/20 0.58
NPC1 O15118 1/20 0.58
KMT2A Q03164 9/20 0.57
MEN1 O00255 7/20 0.57
MAPT P10636 6/20 0.57
NR4A1 P22736 1/20 0.57
MCL1 Q07820 1/20 0.57
GAA P10253 1/20 0.55
KDM4E B2RXH2 2/20 0.54
HTT P42858 1/20 0.54
LMNA P02545 3/20 0.54
TSHR P16473 1/20 0.54
AKR1C3 P42330 1/20 0.54
MAPK1 P28482 1/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132172 0.86 CA1 (0.62) CA1CA2L3MBTL1ALDH1A1POLB
SCHEMBL269558 0.85 CA1 (0.88) CA1CA2RAB9ANPC1KMT2A
SCHEMBL16604876 0.85 CA1 (0.88) CA1CA2RAB9ANPC1KMT2A
SCHEMBL6132158 0.84 KDM4E (0.52) CA1CA2L3MBTL1ALDH1A1POLB
SCHEMBL6132159 0.84 KDM4E (0.52) CA1CA2L3MBTL1ALDH1A1POLB
SCHEMBL6132773 0.84 KDM4E (0.52) CA1CA2L3MBTL1ALDH1A1POLB
SCHEMBL6132284 0.84 ALDH1A1 (0.58) L3MBTL1ALDH1A1POLBRAB9ANPC1
SCHEMBL65696 0.81 ALDH1A1 (0.71) ALDH1A1POLBRAB9ANPC1KMT2A
SCHEMBL20897465 0.80 ALDH1A1 (0.71) CA1CA2L3MBTL1ALDH1A1RAB9A
SCHEMBL2951325 0.80 ALDH1A1 (0.71) L3MBTL1ALDH1A1RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 CA1 1819/4885CA2 1760/4885L3MBTL1 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.